Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis Nov 15, 2021 4:05pm EST
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies Oct 27, 2021 8:00am EDT
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs Oct 05, 2021 4:01pm EDT
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis Aug 23, 2021 7:01am EDT
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates Aug 12, 2021 4:02pm EDT
